Sistema de Salut de Catalunya
Institut Català de la Salut
[Kuwana M] Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; Scleroderma/Myositis Center of Excellence (SMCE) Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan. [Gil-Vila A, Selva-O'Callaghan A] Unitat de Malalties Autoimmunes Sistèmiques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-04-25T14:50:54Z
2022-04-25T14:50:54Z
2021-01-01
Autoanticuerpos; Trastornos reumáticos autoinmunes; Enfermedad pulmonar intersticial
Autoanticossos; Trastorns reumàtics autoimmunes; Malaltia pulmonar intersticial
Autoantibodies; Autoimmune rheumatic disorders; Interstitial lung disease
Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed.
The authors received no financial support for the research, authorship, and/or publication of this article.
Article
Published version
English
Pulmons - Malalties - Complicacions; Malalties autoimmunitàries; Autoanticossos; DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial; Other subheadings::Other subheadings::Other subheadings::/complications; DISEASES::Immune System Diseases::Autoimmune Diseases; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Autoantibodies; ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones; ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::autoanticuerpos
SAGE Publications
Therapeutic Advances in Musculoskeletal Disease;13
https://doi.org/10.1177/1759720X211032457
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3439]
